152 related articles for article (PubMed ID: 31535305)
1. Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands.
Gout-Zwart JJ; de Jong LA; Saptenno L; Postma MJ
Pharmacoecon Open; 2020 Jun; 4(2):321-330. PubMed ID: 31535305
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.
Kim JD; Park CY; Cha BY; Ahn KJ; Kim IJ; Park KS; Lee HW; Min KW; Won JC; Chung MY; Kim JT; Kang JG; Park SW
Clin Ther; 2018 May; 40(5):752-761.e2. PubMed ID: 29729957
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Elsisi GH; Anwar MM; Khattab M; Elebrashy I; Wafa A; Elhadad H; Awad M; Carapinha JL
J Med Econ; 2020 Aug; 23(8):908-914. PubMed ID: 32364032
[No Abstract] [Full Text] [Related]
6. The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands.
van Schoonhoven AV; Schöttler MH; Serné EH; Schrömbges PPG; Postma MJ; Boersma C
J Med Econ; 2023; 26(1):547-553. PubMed ID: 36987694
[TBL] [Abstract][Full Text] [Related]
7. Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.
Alluhidan M; Alabdulkarim H; Alrumaih A; Al-Turaiki A; Alshahrani A; Al-Qahtani S; Alhossan A; Al-Jedai A
J Med Econ; 2023; 26(1):1455-1468. PubMed ID: 37933169
[TBL] [Abstract][Full Text] [Related]
8. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
9. Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran.
Fens T; de Jong L; Kappelhoff B; Boersma C; Postma MJ
J Mark Access Health Policy; 2023; 11(1):2247719. PubMed ID: 37675057
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
11. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study.
Donnelly LA; Morris AD; Pearson ER
Diabetes Obes Metab; 2009 Apr; 11(4):338-42. PubMed ID: 19267712
[TBL] [Abstract][Full Text] [Related]
12. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands.
de Jong LA; van Schoonhoven AV; Hofstra HS; Postma MJ; van Hoek B
J Med Econ; 2021; 24(1):1149-1163. PubMed ID: 34629016
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.
Wang XJ; Wang YH; Li SCT; Gkitzia C; Lim ST; Koh LP; Lim FLWI; Hwang WYK
J Med Econ; 2021; 24(1):637-653. PubMed ID: 33904359
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
16. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
[TBL] [Abstract][Full Text] [Related]
17. Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice.
Fens T; van der Pol S; Kocks JWH; Postma MJ; van Boven JFM
Value Health; 2019 Oct; 22(10):1092-1101. PubMed ID: 31563251
[TBL] [Abstract][Full Text] [Related]
18. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.
Griffin SJ; Bethel MA; Holman RR; Khunti K; Wareham N; Brierley G; Davies M; Dymond A; Eichenberger R; Evans P; Gray A; Greaves C; Harrington K; Hitman G; Irving G; Lessels S; Millward A; Petrie JR; Rutter M; Sampson M; Sattar N; Sharp S
Health Technol Assess; 2018 Apr; 22(18):1-64. PubMed ID: 29652246
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
